image
Healthcare - Biotechnology - NASDAQ - US
$ 4.11
-0.243 %
$ 217 M
Market Cap
-2.14
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SCPH stock under the worst case scenario is HIDDEN Compared to the current market price of 4.11 USD, scPharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SCPH stock under the base case scenario is HIDDEN Compared to the current market price of 4.11 USD, scPharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one SCPH stock under the best case scenario is HIDDEN Compared to the current market price of 4.11 USD, scPharmaceuticals Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SCPH

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
36.3 M REVENUE
167.28%
-64.8 M OPERATING INCOME
-16.93%
-85.1 M NET INCOME
-55.35%
-70.5 M OPERATING CASH FLOW
-19.06%
29.3 M INVESTING CASH FLOW
46.75%
70.1 M FINANCING CASH FLOW
371.92%
11.8 M REVENUE
-3.28%
-17.8 M OPERATING INCOME
-8.65%
-19.7 M NET INCOME
-4.76%
-17.1 M OPERATING CASH FLOW
-12.86%
0 INVESTING CASH FLOW
100.00%
-972 K FINANCING CASH FLOW
-54.04%
Balance Sheet scPharmaceuticals Inc.
image
Current Assets 106 M
Cash & Short-Term Investments 75.7 M
Receivables 11.7 M
Other Current Assets 18.5 M
Non-Current Assets 1.67 M
Long-Term Investments 0
PP&E 1.33 M
Other Non-Current Assets 341 K
70.36 %10.90 %17.18 %Total Assets$107.5m
Current Liabilities 14.9 M
Accounts Payable 3.88 M
Short-Term Debt 478 K
Other Current Liabilities 10.5 M
Non-Current Liabilities 79.3 M
Long-Term Debt 52.5 M
Other Non-Current Liabilities 26.9 M
4.12 %11.16 %55.68 %28.52 %Total Liabilities$94.2m
EFFICIENCY
Earnings Waterfall scPharmaceuticals Inc.
image
Revenue 36.3 M
Cost Of Revenue 11.4 M
Gross Profit 25 M
Operating Expenses 89.7 M
Operating Income -64.8 M
Other Expenses 20.4 M
Net Income -85.1 M
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)36m(11m)25m(90m)(65m)(20m)(85m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.73% GROSS MARGIN
68.73%
-178.29% OPERATING MARGIN
-178.29%
-234.36% NET MARGIN
-234.36%
-639.25% ROE
-639.25%
-79.19% ROA
-79.19%
-69.56% ROIC
-69.56%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis scPharmaceuticals Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -85.1 M
Depreciation & Amortization 20 K
Capital Expenditures -21 K
Stock-Based Compensation 5.44 M
Change in Working Capital -13.1 M
Others 22.2 M
Free Cash Flow -70.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets scPharmaceuticals Inc.
image
Wall Street analysts predict an average 1-year price target for SCPH of $13 , with forecasts ranging from a low of $13 to a high of $13 .
SCPH Lowest Price Target Wall Street Target
13 USD 216.30%
SCPH Average Price Target Wall Street Target
13 USD 216.30%
SCPH Highest Price Target Wall Street Target
13 USD 216.30%
Price
Max Price Target
Min Price Target
Average Price Target
14141212101088664422Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership scPharmaceuticals Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
2 M USD 1
9-12 MONTHS
7. News
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025 Shares of scPharmaceuticals have lost 37% over the past 3 years and are down 11% in 2025. Furoscix's subcutaneous administration offers the potential to keep heart failure patients at home longer and cut down on hospital readmissions. Q1 seasonality is in the rearview mirror, with multiple tailwinds, including Medicare redesign and label expansion, to fuel growth going forward. seekingalpha.com - 3 weeks ago
scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants William Thorpe - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good afternoon and welcome to scPharmaceuticals First Quarter 2025 Earnings Conference Call. seekingalpha.com - 1 month ago
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.36 per share a year ago. zacks.com - 1 month ago
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX ® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14 th , at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. globenewswire.com - 1 month ago
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET globenewswire.com - 1 month ago
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: globenewswire.com - 1 month ago
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call. seekingalpha.com - 2 months ago
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.35 per share a year ago. zacks.com - 2 months ago
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million globenewswire.com - 2 months ago
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET globenewswire.com - 3 months ago
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome globenewswire.com - 3 months ago
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago
8. Profile Summary

scPharmaceuticals Inc. SCPH

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 217 M
Dividend Yield 0.00%
Description scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Contact 2400 District Avenue, Burlington, MA, 01803 https://www.scpharmaceuticals.com
IPO Date Nov. 17, 2017
Employees 162
Officers Mr. Steve C. Parsons Senior Vice President of Commercial Mr. John H. Tucker President, Chief Executive Officer, Principal Executive Officer & Director Ms. Rachael Nokes Chief Financial Officer Dr. John Mohr Pharm.D. Senior Vice President of Clinical Development & Medical Affairs Ms. Katherine Taudvin Vice President of Corporate Affairs & Human Resources Mr. Michael D. Hassman Senior Vice President of Technical Operations